New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension-Reference-Cited by-同舟云学术

New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension

Published:2019-08-26 Issue:16 Volume:26 Page:2844-2864
ISSN:0929-8673
Container-title:Current Medicinal Chemistry
language:en
Short-container-title:CMC

Author:

Mercurio Valentina¹,Bianco Anna¹,Campi Giacomo¹,Cuomo Alessandra¹,Diab Nermin²,Mancini Angela¹,Parrella Paolo¹,Petretta Mario¹,Hassoun Paul M.³,Bonaduce Domenico¹

Affiliation:

1. Federico II University, Department of Translational Medical Sciences, Naples, Italy

2. University of Ottawa, Department of Medicine, Ottawa, ON, Canada

3. Johns Hopkins University, Division of Pulmonary and Critical Care Medicine, Baltimore, MD, United States

Abstract

Despite recent advances in Pulmonary Arterial Hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signaling pathways and investigational drugs with promising role in the treatment of PAH.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry

Reference149 articles.

1. Hoeper M.M.; Bogaard H.J.; Condliffe R.; Frantz R.; Khanna D.; Kurzyna M.; Langleben D.; Manes A.; Satoh T.; Torres F.; Wilkins M.R.; Badesch D.B.; Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol [http://dx.doi.org/10.1016/j.jacc.2013.10.032]. [PMID: 24355641].2013,62(25)(Suppl.),D42-D50

2. Galiè N.; Humbert M.; Vachiery J.L.; Gibbs S.; Lang I.; Torbicki A.; Simonneau G.; Peacock A.; Vonk Noordegraaf A.; Beghetti M.; Ghofrani A.; Gomez Sanchez M.A.; Hansmann G.; Klepetko W.; Lancellotti P.; Matucci M.; McDonagh T.; Pierard L.A.; Trindade P.T.; Zompatori M.; Hoeper M.; Aboyans V.; Vaz Carneiro A.; Achenbach S.; Agewall S.; Allanore Y.; Asteggiano R.; Paolo Badano L.; Albert Barbera J.; Bouvaist H.; Bueno H.; Byrne R.A.; Carerj S.; Castro G.; Erol C.; Falk V.; Funck-Brentano C.; Gorenflo M.; Granton J.; Iung B.; Kiely D.G.; Kirchhof P.; Kjellstrom B.; Landmesser U.; Lekakis J.; Lionis C.; Lip G.Y.; Orfanos S.E.; Park M.H.; Piepoli M.F.; Ponikowski P.; Revel M.P.; Rigau D.; Rosenkranz S.; Voller H.; Luis Zamorano J.; 2015 esc/ers guidelines for the diagnosis and treatment of pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (esc) and the european respiratory society (ers): Endorsed by: Association for European paediatric and congenital cardiology (aepc), international society for heart and lung transplantation (ishlt). Eur Heart J [http://dx.doi.org/10.1093/eurheartj/ehv317]. [PMID: 26320113].2016,37(1),67-119

3. Galiè N.; Brundage B.H.; Ghofrani H.A.; Oudiz R.J.; Simonneau G.; Safdar Z.; Shapiro S.; White R.J.; Chan M.; Beardsworth A.; Frumkin L.; Barst R.J.; Tadalafil therapy for pulmonary arterial hypertension. Circulation [http://dx.doi.org/10.1161/CIRCULATIONAHA.108.839274]. [PMID: 19470885].2009,119(22),2894-2903

4. Galiè N.; Olschewski H.; Oudiz R.J.; Torres F.; Frost A.; Ghofrani H.A.; Badesch D.B.; McGoon M.D.; McLaughlin V.V.; Roecker E.B.; Gerber M.J.; Dufton C.; Wiens B.L.; Rubin L.J.; Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation [http://dx.doi.org/10.1161/CIRCULATIONAHA.107.742510]. [PMID: 18506008].2008,117(23),3010-3019

5. Benza R.L.; Miller D.P.; Barst R.J.; Badesch D.B.; Frost A.E.; McGoon M.D.; An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest [http://dx.doi.org/10.1378/chest.11-1460]. [PMID: 22281797].2012,142(2),448-456

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of High-Flow Nasal Cannula on Right Heart Dysfunction in Patients with Acute-on-Chronic Respiratory Failure and Pulmonary Hypertension;Journal of Clinical Medicine;2023-08-23

2. Inhibition of miR-4640-5p alleviates pulmonary hypertension in chronic obstructive pulmonary disease patients by regulating nitric oxide synthase 1;Respiratory Research;2023-03-24

3. When more is more: the role of additional upfront therapy in pulmonary arterial hypertension;ERJ Open Research;2023-01

4. Mildly Elevated Pulmonary Hypertension;Heart Failure Clinics;2023-01

5. MKI67 as a potential diagnostic biomarker in pulmonary hypertension;Frontiers in Pediatrics;2022-11-01